A 2026 review published in Expert Opinion on Drug Delivery (Nayak et al.) synthesises current semaglutide therapy trends and the principal strategies under investigation to overcome its sub-1% oral bioavailability. Subcutaneous formulations remain the clinical gold standard, while SNAC-enabled oral tablets, lipid nanoparticle carriers, and microneedle patch systems represent the leading next-generation delivery approaches.
What Is Semaglutide and How Does It Work at the Receptor Level?
Semaglutide is a C18 fatty-acid-conjugated GLP-1 analogue with two structural modifications — an Aib8 substitution and an Arg34Lys swap — that confer DPP-4 resistance and high-affinity albumin binding, extending plasma half-life to approximately 165–168 hours. At GLP-1R, it acts as a full agonist, amplifying glucose-dependent insulin secretion and suppressing glucagon release.
GLP-1 receptors are expressed in pancreatic beta cells, the hypothalamus, the brainstem, and peripheral tissues including the heart and kidney. Semaglutide's agonism at hypothalamic GLP-1R reduces appetite signalling and slows gastric emptying, contributing to the sustained caloric deficit observed in STEP-programme trials. Receptor occupancy studies confirm that the C18 fatty acid chain tethers semaglutide to circulating albumin, dramatically reducing renal filtration and extending systemic exposure.
The albumin-binding strategy underpins semaglutide's pharmacokinetic superiority over earlier GLP-1 analogues such as liraglutide (t½ ≈ 13 hours). A single subcutaneous dose achieves absolute bioavailability of approximately 89%, with peak plasma concentration (Tmax) at 24–36 hours post-injection. This flat, sustained concentration profile underpins both its glycaemic efficacy and its tolerability advantage over shorter-acting agents.
What Are the Current Clinical Trends in Semaglutide Therapy as of 2026?
By 2026, semaglutide has expanded well beyond glycaemic control into cardiovascular risk reduction, obesity pharmacotherapy, and emerging indications including metabolic-associated steatohepatitis (MASH) and chronic kidney disease. The SELECT trial demonstrated a 20% relative reduction in major adverse cardiovascular events (MACE) in non-diabetic patients with overweight or obesity, cementing its role as a cardiometabolic agent.
The STEP 1 trial established a mean body weight reduction of approximately 14.9% at 68 weeks with 2.4 mg once-weekly subcutaneous semaglutide plus lifestyle intervention, and STEP 5 confirmed durable weight loss of approximately 15% at 104 weeks. These outcomes have driven regulatory approvals beyond type 2 diabetes and positioned semaglutide as the benchmark against which newer incretin agonists are measured.
Oral semaglutide (Rybelsus, 7–14 mg) is approved for type 2 diabetes management and demonstrated non-inferiority to subcutaneous semaglutide on HbA1c reduction in PIONEER 7. However, the oral formulation's absolute bioavailability remains below 1%, creating a persistent clinical gap between the two routes. Researchers are therefore investigating multiple delivery strategies to close this gap without sacrificing the convenience of oral administration.
Why Is Oral Bioavailability of Semaglutide Below 1% and What Barriers Must Be Overcome?
Three overlapping barriers suppress oral semaglutide bioavailability: proteolytic degradation by gastric pepsin and intestinal peptidases, low epithelial permeability, and rapid first-pass hepatic extraction. Together these reduce the fraction of an oral dose reaching systemic circulation to roughly 0.4–1%, compared with ~89% for subcutaneous injection, requiring a roughly 28-fold dose amplification to achieve equivalent plasma exposure.
Pepsin activity at gastric pH 1–3 cleaves peptide bonds within semaglutide's backbone before it can reach absorptive epithelium. Even if the peptide survives gastric transit, the tight junctions of intestinal enterocytes present a second barrier: semaglutide's molecular weight (~4,114 Da) and hydrophilicity restrict passive transcellular diffusion. Paracellular transport is similarly limited because tight junction opening is transient and non-selective.
First-pass hepatic metabolism adds a third layer of attrition. Portal blood delivers absorbed peptide directly to hepatic peptidases before systemic distribution occurs. The cumulative effect means that even with absorption enhancers, the therapeutic dose of oral semaglutide must be set at 14 mg to achieve plasma exposures equivalent to a 0.5 mg subcutaneous dose.
How Does SNAC Technology Enable Gastric Absorption of Oral Semaglutide?
Salcaprozate sodium (SNAC) is a small-molecule absorption enhancer co-formulated with oral semaglutide in a 1:300 molar ratio. SNAC raises local gastric pH in the microenvironment around the dissolving tablet, protecting semaglutide from pepsin hydrolysis. It also intercalates into gastric epithelial lipid membranes, transiently increasing transcellular permeability and enabling direct gastric — rather than intestinal — absorption of the peptide.
The gastric absorption route is mechanistically distinct from conventional oral drug absorption. Semaglutide is released from the tablet as multimers that are shielded from acidic pH within the SNAC-buffered microenvironment. As SNAC partitions into the gastric mucosa, it creates a transient lipophilic channel through which semaglutide monomers can traverse the epithelium. This mechanism was confirmed in a landmark 2018 Science Translational Medicine study using gastric cannulation in pigs.
Despite SNAC's ingenuity, the resulting bioavailability remains highly variable (coefficient of variation ~50%) and sensitive to administration conditions. Rybelsus must be taken with no more than 120 mL of water on an empty stomach, with a mandatory 30-minute fast before eating. Food, additional water volume, or co-administration of proton pump inhibitors each significantly reduce absorption, limiting real-world adherence and consistent plasma exposure.
What Novel Delivery Strategies Are Being Investigated to Improve Semaglutide Bioavailability?
The 2026 Nayak et al. review identifies four principal engineering strategies under active investigation: lipid nanoparticle (LNP) encapsulation, polymeric nanoparticle systems, mucoadhesive formulations, and transdermal microneedle patches. Each approach targets a distinct barrier — enzymatic degradation, epithelial permeability, or dosing-condition sensitivity — and several have demonstrated improved bioavailability in preclinical models.
Lipid nanoparticles encapsulate semaglutide within a phospholipid shell that shields the peptide from luminal proteases and facilitates endocytic uptake by enterocytes. A 2024 preclinical study reported that LNP-formulated semaglutide achieved approximately 3–5 fold higher oral bioavailability than SNAC tablets in rodent models, though translation to human pharmacokinetics remains unconfirmed. The LNP approach also offers the potential for lymphatic absorption, bypassing first-pass hepatic extraction entirely.
Polymeric nanoparticles using PLGA or chitosan matrices provide pH-responsive protection: the polymer shell remains intact in the acidic stomach but dissolves at intestinal pH 6–7, releasing semaglutide at the absorptive surface of the small intestine. Chitosan-based systems additionally exploit the polymer's mucoadhesive properties to prolong residence time at the epithelial surface, increasing the window for transcellular uptake.
Transdermal microneedle patches represent a needle-free alternative to subcutaneous injection. Dissolving microneedle arrays loaded with semaglutide penetrate the stratum corneum and deposit drug into the dermis, where it is absorbed into dermal capillaries. Daewoong Therapeutics reported best-in-class bioavailability data for a semaglutide microneedle patch in 2024, with once-weekly application feasibility demonstrated in preclinical studies.
How Do Mucoadhesive and Enteric-Coating Approaches Complement Nanoparticle Strategies?
Mucoadhesive polymers such as carbopol, HPMC, and thiolated chitosan extend gastrointestinal residence time by anchoring the formulation to the mucosal surface, prolonging contact between semaglutide and absorptive epithelium. When combined with enteric coatings that dissolve above pH 5.5, these systems can target drug release to the proximal jejunum, where peptide transporter density and permeability are highest.
Enteric-coated capsules protect semaglutide from gastric acid and pepsin by maintaining an intact polymer shell below pH 5.5. Once the capsule reaches the duodenum or jejunum, the coating dissolves and releases the peptide payload in a controlled manner. This approach eliminates the strict fasting and water-volume requirements of SNAC tablets, potentially improving real-world adherence.
Combination strategies — for example, SNAC co-formulated with a mucoadhesive excipient and an enteric coat — are also under investigation. A 2024 Journal of Controlled Release study examined SNAC combined with capric acid (C10) in tablet formulations, finding that the dual-enhancer system produced additive improvements in gastric mucosal permeation compared with either enhancer alone. These combinatorial approaches reflect the field's recognition that no single strategy is sufficient to overcome all three bioavailability barriers simultaneously.
What Safety Considerations Apply to Current and Emerging Semaglutide Protocols?
Semaglutide's established safety profile includes dose-dependent gastrointestinal adverse events — nausea, vomiting, diarrhoea, and constipation — that typically resolve within 4–8 weeks of dose escalation. Rare but serious risks include acute pancreatitis, gallbladder disease, and a theoretical thyroid C-cell tumour risk from rodent data not yet confirmed in humans. Novel delivery systems require independent excipient safety evaluation.
SNAC itself has a well-characterised safety profile from clinical use in oral semaglutide and oral vitamin B12 formulations. Lipid nanoparticle excipients (ionisable lipids, PEGylated lipids) carry theoretical immunogenicity risks that have not been systematically evaluated for chronic oral peptide delivery. Regulatory agencies will require long-term safety data on novel carrier systems before approval, particularly given the chronic dosing schedules typical of metabolic disease management.
Practitioners should note that semaglutide's gastric-emptying delay can alter the absorption kinetics of co-administered oral medications. This pharmacodynamic interaction is not formulation-specific — it applies to both subcutaneous and oral routes. Clinically relevant interactions have been reported with levothyroxine, oral contraceptives, and certain antibiotics where time-sensitive absorption is critical. How Do You Cycle GH Peptides Without Crashing Endogenous Production in 2026? What Does the 2026 Clinical Evidence Actually Show for BPC-157 in Shoulder Rotator Cuff Tears? What Does 2026 Research Reveal About BPC-157 for Musculoskeletal Healing — Regeneration or Risk?